




RealRate

PHARMACEUTICAL 2020

SELLAS Life Sciences Group Inc. Rank 286 of 358





RealRate

PHARMACEUTICAL 2020

SELLAS Life Sciences Group Inc. Rank 286 of 358



The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 78% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 101% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	8,242
Cost of Goods Sold	0
Intangible Assets	1,914
Liabilities, Current	5,290
Liabilities, Non-Current	0
Other Assets	6,453
Other Compr. Net Income	0
Other Expenses	2,752
Other Liabilities	5,226
Other Net Income	668
Other Revenues	0
Property and Equipment	0
Research and Development	7,285
Selling, General and Administrative Expense	9,923

Output Variable	Value in 1000 USD
Assets	16,609
Liabilities	10,516
Expenses	19,960
Revenues	0
Stockholders Equity	6,093
Net Income	-19,292
Comprehensive Net Income	-19,292
Economic Capital Ratio	-65%